Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD + Calaspargase Pegol in Young Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT05581030Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of calaspargase pegol in acute lymphoblastic leukemia (ALL), sponsored by Moffitt Cancer Center. Primary endpoint: Mortality Rate of Hyper-CVAD after first infusion of calaspargase pegol at 12 months. Started May 2023; status: recruiting.
02
Drugs
calaspargase pegol
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05581030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581030.